Amit Singal, MD, MS - Harmonizing HCC Care With a Multidisciplinary Ensemble: Guidance for the Era of Novel Locoregional, Multimodal, and Systemic Strategies

PeerView Gastroenterology CME/CNE/CPE Video Podcast

Go online to PeerView.com/ZQB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This Seminar & Multidisciplinary Tumor Board program will pair insightful commentary on emerging systemic and locoregional options in HCC with clinical insights from different disciplines. Each Tumor Board segment will feature a case-centered discussion on the increasingly important multidisciplinary team-based management of patients across the HCC disease continuum. Hear an in-depth conversation on how the HCC management team can successfully collaborate to offer the best possible care to their patients. Upon completion of this CE activity, participants will be better able to: Assess the latest efficacy and safety evidence on available and emerging systemic treatments, including multikinase inhibitors, anti-angiogenic agents, and immune checkpoint inhibitors (as monotherapy or within a combination strategy) for patients with advanced HCC, Review ongoing clinical trials and recent data for innovative strategies, including tumor treating fields, and locoregional combinations with systemic therapies, across the HCC disease spectrum, Develop personalized treatment plans for patients with early- to advanced-stage HCC, inclusive of clinical trial enrollment when appropriate, that are based on the latest clinical evidence, practice guidelines, treatment history, and other patient- and disease-specific factors, Apply best practices for collaboration and coordination of care among the multidisciplinary HCC care team to optimize patient assessment and treatment and minimize treatment-related toxicities.